Gliclazide: Clinical Trials

5 trials of Gliclazide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 withdrawn. 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 15Completed 4, Withdrawn 1

Follow Gliclazide: new trials by email Literature Review of Gliclazide trials Research Report on Gliclazide

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers
Omeprazole, Placebo oral tablet, Gliclazide - Diabetes Mellitus, Type 2
Phase 1CompletedUniversity of Sarajevo152019-03-042021-08-18
Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants
Metformin/Gliclazide Fixed Combination, Metformin, Gliclazide - Healthy
Phase 1CompletedMerck KGaA, Darmstadt, Germany402018-02-162019-07-16
Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations
BF-Gliclazide Tablet 80mg, Diamicron 80mg Tablet - Healthy
Phase 1CompletedBright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited172016-01-012016-07-25
Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets
Gliclazide 120 mg MR Tablets Formula A, Gliclazide 120 mg MR Tablets, Gliclazide 120 mg MR Tablets Formula B - Comparative Bioavailability
Phase 1WithdrawnDisphar International B.V.2014-06-012016-12-02
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers
BIA 2-093, Gliclazide - Epilepsy
Phase 1CompletedBial - Portela C S.A.202007-10-012016-05-19

Conditions studied

Diabetes Mellitus, Type 2 (1)  ·  Epilepsy (1)

Sponsors

Bial - Portela C S.A. (1)  ·  Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited (1)  ·  Disphar International B.V. (1)  ·  Merck KGaA, Darmstadt, Germany (1)  ·  University of Sarajevo (1)

Countries

Bosnia and Herzegovina (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Jordan (1)  ·  Portugal (1)

Top investigators

Aida Kulo Cesic, PhD (1)  ·  Brian Tomlinson (1)  ·  N. Najib, Pharm. Ph.D (1)  ·  Risa Ozaki (1)  ·  Tanja Dujic, PhD (1)  ·  Vincent HL Lee (1)